Active — Not RecruitingNot Applicable

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

United States206 participantsStarted 2022-06-13

Plain-language summary

This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Written informed consent obtained prior to registration of any patient data * Male or female patients aged 18 years or older with endogenous CS treated with osilodrostat. Treatment with osilodrostat can either be initiated at the first visit of the study or can have been initiated before screening. Exclusion Criteria: * Patients with exogenous CS * Patients with Pseudo CS * Patients participating in an interventional clinical trial with an investigational drug.

What they're measuring

Incidence of osilodrostat-related adverse events and serious adverse events

Timeframe: 3 years of treatment with osilodrostat

Trial details

NCT IDNCT05382156

SponsorRECORDATI GROUP

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-06

View on ClinicalTrials.gov More Endogenous Cushing's Syndrome trials